Welcome to the EAS 2023 Interactive Program

From evidence to action with elevated Lp(a): perspectives on clinical implications and testing - Industry Sponsored Session by Novartis. Novartis invites you to join our esteemed faculty at an engaging Medical Special Lecture on lipoprotein(a) [Lp(a)] in ASCVD and AVS. In this session, Professor Hilgendorf from Germany will introduce the session and briefly discuss the prevalence of elevated Lp(a) levels and the reality of Lp(a) testing in clinical practice. Professor Ballantyne from the USA will take us through the science behind the role of Lp(a) in ASCVD and AVS, data from real-world studies, and the compounds targeting Lp(a) currently in development. Professor Kronenberg from Austria will discuss insights from the EAS consensus statement on Lp(a) from 2022, including the impact of elevated Lp(a) on ASCVD risk, the importance of Lp(a) testing, and what we can do now to manage patients. The presentations will be followed by a 10-minute Q&A session.